Risk factors predicting prostate cancer

Authors

Keywords:

Cáncer de próstata, factores de riesgo predictivos, PSA, epidemiología

Abstract

Introduction: Prostate cancer (PCa) is one of the most prevalent malignancies in men worldwide and represents a significant public health problem. The identification of predictive factors is crucial to improve its prevention and early detection.

Objective: This study analyzes modifiable and non-modifiable risk factors in an Ecuadorian population.

Material and method: An observational study was conducted in patients treated in the Urology service of Hospital XXX during the XXX period. Risk variables classified into two groups were analyzed: non-modifiable (age, ethnicity and family history) and modifiable (previous prostate diseases, sexually transmitted infections, obesity, smoking and alcoholism). A univariate and bivariate statistical analysis with binary logistic regression was used to determine the relationship between risk factors and the presence of PCa.

Results: Main predictive factors identified were advanced age, family history of PCa, and previous prostate diseases. Men older than 65 years and those with a family history were found to have a significantly higher risk of developing the disease. Likewise, the presence of previous prostate diseases showed the greatest association with the onset of PCa.

Conclusions: Age, elevated PSA, and family history are key determinants in the assessment of PCa risk in the Ecuadorian population. The inclusion of predictive models that combine clinical biomarkers and epidemiological factors could improve diagnostic accuracy and optimize prevention strategies.

Downloads

Download data is not yet available.

References

1. World Health Organization. International Agency for Research of Cancer. Estimated age-standardized prostate cancer incidence (world) [Internet]. Francia: GLOBOCAN; 2020 [Citado 01/02/2025]. Disponible en: http://gco.iarc.fr/today

2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin [Internet]. 2021[Citado 01/02/2025];71(3):209-49. Disponible en: https://doi.org/10.3322/caac.21660

3. Rawla P. Epidemiology of Prostate Cancer. World J Oncol. [Internet]. 2019 [Citado 01/02/2025];10(2):63-89. Disponible en: https://doi.org/10.14740/wjon1191

4. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. [Internet]. 2022 [Citado 01/02/2025];72(1):7-33. Disponible en: https://doi.org/10.3322/caac.2170

5. Mumuni S, O’Donnell C, Doody O. The Risk Factors and Screening Uptake for Prostate Cancer: A Scoping Review. Healthcare [Internet]. 2023 [Citado 01/02/2025];11(2780). Disponible en: Disponible en: https://doi.org/10.3390/healthcare11202780

6. Gandaglia G, Leni R, Bray F, Fleshner N, Freedland SJ, Kibel AS. Epidemiology and prevention of prostate cancer. Eur Urol Oncol [Internet]. 2021[Citado 01/02/2025];4(6):877-92. Disponible en: https://doi.org/10.1016/j.euo.2021.09.006

7. Nair SS, Chakravarty D, Dovey ZS, Zhang X, Tewari AK. Why do African-American men face higher risks for lethal prostate cancer?. Curr Opin Urol [Internet]. 2022 [Citado 01/02/2025];32(1):96-101. Disponible en: https://doi.org/10.1097/MOU.0000000000000951

8. Coughlin SS. A review of social determinants of prostate cancer risk, stage, and survival. Prostate Int [Internet]. 2020 [Citado 01/02/2025];8(2):49-54. Disponible en: https://doi.org/10.1016/j.prnil.2019.08.001

9. Das H, Rodriguez R. Health Care Disparities in Urologic Oncology: A Systematic Review. Urology [Internet]. 2020 [Citado 01/02/2025];136:9-18. Disponible en: https://doi.org/10.1016/j.urology.2019.09.058

10. Heidegger I. PSA screening—A matter of debate? Memo-Mag. Eur Med Oncol [Internet]. 2019 [Citado 01/02/2025];12:244-8. Disponible en: https://doi.org/10.1007/s12254-019-00524-9

11. Wilson KM, Mucci LA. Diet and lifestyle in prostate cancer. Adv Exp Med Biol [Internet]. 2019 [Citado 01/02/2025];1210:1-27. Disponible en: https://doi.org/10.1007/978-3-030-32656-2_1

12. Pernar CH, Ebot EM, Pettersson A, Gerke T, Lutz S, Markozannes G, et al. A prospective study of the association between physical activity and risk of prostate cancer defined by clinical features and TMPRSS2:ERG. Eur Urol [Internet]. 2019 [Citado 01/02/2025];76(1):33-40. Disponible en: https://doi.org/10.1016/j.eururo.2018.09.041

13. Ledda C, Bracci M, Spadafora A, Motta G, Smecca G, Catelan D, et al. Unmasking the hidden danger: a decade-long systematic review of case-control studies on single occupational risks and prostate cancer. Life (Basel) [Internet]. 2023 [Citado 01/02/2025];13(9):1820. Disponible en: https://doi.org/10.3390/life13091820

14. Olsson A, Kromhout H. Occupational cancer burden: the contribution of exposure to process-generated substances at the workplace. Mol Oncol [Internet]. 2021 [Citado 01/02/2025];15(3):753-63. Disponible en: https://doi.org/10.1002/1878-0261.12925

15. Huang J, Chan EO, Liu X, Wu F, Tang J, Liang H, et al. Global trends of prostate cancer by age, and their associations with gross domestic product (GDP), human development index (HDI), smoking, and alcohol drinking. Clin Genitourin Cancer [Internet]. 2023 [Citado 01/02/2025];21(4):e261-e70. Disponible en: https://doi.org/10.1016/j.clgc.2023.02.003

16. Van Poppel H, Roobol MJ, Chapple CR, Catto JW, N'Dow J, Sønksen J, et al. Prostate-specific antigen testing as part of a risk-adapted early detection strategy for prostate cancer: European Association of Urology position and recommendations for 2021. Eur Urol [Internet]. 2021 [Citado 01/02/2025];80(6):703-11. Disponible en: https://doi.org/10.1016/j.eururo.2021.07.024

17. Gulati R, Psutka SP, Etzioni R. Personalized risks of overdiagnosis for screen-detected prostate cancer incorporating patient comorbidities: estimation and communication. J Urol [Internet]. 2019 [Citado 01/02/2025];202(5):936-43. Disponible en: https://doi.org/10.1097/JU.0000000000000346

18. David MK, Leslie SW. Prostate-specific antigen [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. [Citado 01/02/2025]. Disponible en: https://www.ncbi.nlm.nih.gov/sites/books/NBK557495/

19. Aladwani M, Lophatananon A, Ollier W, Muir K. Prediction models for prostate cancer to be used in the primary care setting: a systematic review. BMJ Open [Internet]. 2020 [Citado 01/02/2025];10(7):e034661. Disponible en: https://doi.org/10.1136/bmjopen-2019-034661

20. Hwang T, Oh H, Lee JA, Lee C, Kim S, Park J, et al. Prostate cancer risk prediction based on clinical factors and prostate-specific antigen. BMC Urol [Internet]. 2023 [Citado 01/02/2025];23:100. Disponible en: https://doi.org/10.1186/s12894-023-01259-w

21. Oderda M, Dematteis A, Calleris G, Conti A, D’Agate D, Falcone M, et al. Predictors of prostate cancer at fusion biopsy: the role of positive family history, hypertension, diabetes, and body mass index. Curr Oncol [Internet]. 2023 [Citado 01/02/2025];30(5):4957-65. Disponible en: https://doi.org/10.3390/curroncol30050374

22. Liang RS, Lim J, Sothilingam S, Sien W, Nazran A, Ong TA. Predictive factors of prostate cancer diagnosis with PSA 4.0-10.0 ng/ml in a multi-ethnic Asian population, Malaysia. Asian J Surg [Internet]. 2020 [Citado 01/02/2025];43(1):87-94. Disponible en: https://doi.org/10.1016/j.asjsur.2019.02.014

23. Saliev T, Akhmad N, Altynbekova S, Nogaeva M, Tazhieva A, Dushimova Z. Role of ethnic and genetic factors in the development of prostate cancer: a review. World Acad Sci J [Internet]. 2025 [Citado 01/02/2025];7(1):13. Disponible en: https://doi.org/10.3892/wasj.2024.301

24. García YY, Calle R, Arellano JE, Rodríguez MR, Fernández RM. Niveles de antígeno prostático específico total y factores de riesgo en adultos mayores del centro salud Morro Solar – Jaén 2023. LATAM [Internet]. 2023 [Citado 01/02/2025];4(6):975-87. Disponible en: https://latam.redilat.org/index.php/lt/article/view/1498

25. American Cancer Society. Estadísticas importantes sobre el cáncer de próstata [Internet]. EE UU: American Cancer Society; 2025 [Citado 01/02/2025]. Disponible en: https://www.cancer.org/es/cancer/tipos/cancer-de-prostata/acerca/estadisticas-clave.html?utm_source=chatgpt.com

26. Saka A, Giaquinto A, McCullough L, Tossas K, Star J, Jemal A, et al. Cancer statistics for African American and Black people, 2025. CA Cancer J Clin [Internet]. 2025 [Citado 01/02/2025];75(2):111‐40. Disponible en: https://doi.org/10.3322/caac.21874

27. Hage C, Agarwal N. Racial and ethnic disparities in prostate cancer-correlation with incidence and progression. JAMA Netw Open [Internet]. 2024 [Citado 01/02/2025];7(11):e2445522. Disponible en: https://doi.org/10.1001/jamanetworkopen.2024.45522

28. Hwang T, Oh H, Lee JA, Kim EJ. Prostate cancer risk prediction based on clinical factors and prostate-specific antigen. BMC Urol [Internet]. 2023 [Citado 01/02/2025];23:100. Disponible en: https://doi.org/10.1186/s12894-023-01259-w

Downloads

Published

2025-06-30

How to Cite

1.
Caicedo Rodríguez JO, López Barrionuevo C, Armijos Moreta JF, Rodríguez Cuéllar Y, Burbano Pijal D. Risk factors predicting prostate cancer. Rev haban cienc méd [Internet]. 2025 Jun. 30 [cited 2025 Jul. 1];24:e6001. Available from: https://revhabanera.sld.cu/index.php/rhab/article/view/6001

Issue

Volume 24 (2025): continuous publication

Section

Clinical and pathological sciences

License

Copyright (c) 2025 Revista Habanera de Ciencias Médicas

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All the content of this magazine is in Open Access, distributed according to the terms of the Creative Commons Attribution-Noncommercial 4.0 License that allows non-commercial use, distribution and reproduction without restrictions in any medium, provided that the primary source is duly cited.